• COVID-19
  • Biosimilars
  • Cataract Therapeutics
  • DME
  • Gene Therapy
  • Workplace
  • Ptosis
  • Optic Relief
  • Imaging
  • Geographic Atrophy
  • AMD
  • Presbyopia
  • Ocular Surface Disease
  • Practice Management
  • Pediatrics
  • Surgery
  • Therapeutics
  • Optometry
  • Retina
  • Cataract
  • Pharmacy
  • IOL
  • Dry Eye
  • Understanding Antibiotic Resistance
  • Refractive
  • Cornea
  • Glaucoma
  • OCT
  • Ocular Allergy
  • Clinical Diagnosis
  • Technology

Hybrid contact lens receives FDA nod


Carlsbad, CA—The FDA has given SynergEyes Inc. approval to market SynergEyes A hybrid contact lenses to correct hyperopic, myopic, and astigmatic errors, including presbyopia.

The lens features a high-Dk rigid gas-permeable (RGP) center with a hydrophilic, non-ionic soft skirt and will correct ametropia from –20 to 20 D with up to 6 D of astigmatism. A patent-pending HyperBond junction technology provides a strong interface between the soft and rigid portions of the lens, the company said.

SynergEyes, which plans a fall launch, said the lens offers the visual acuity of an RGP lens and the all-day comfort of a soft lens. It plans to expand its hybrid lens line to include lenses specifically for patients with keratoconus, presbyopia, and post-surgical vision correction needs.

Related Videos
EyeCon Co-chair Oluwatosin U. Smith, MD: Passion for Research and Education Drives Her Commitment to Ophthalmology
© 2024 MJH Life Sciences

All rights reserved.